PATENTS
Application for order prohibiting Minister from issuing notice of compliance to ratiopharm until after expiration of Canadian Patent 1321393 (′393)—Pfizer listed two patents on Patent Register against “Norvasc” (brand name for amlodipine, cardiac drug acting as calcium channel blocker), patent not valid selection patent—Applicant not disproving ratiopharm’s allegation of invalidity for obvious double patenting—Application dismissed.
Pfizer Canada Inc. v. Canada (Minister of Health) (T‑1350‑04, 2006 FC 220, von Finckenstein J., order dated 17/2/06, 24 pp.)
You are being directed to the most recent version of the statute which may not be the version considered at the time of the judgment.